View in EDS

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial.

Saved in:
Bibliographic Details
Title: Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial.
Authors: Kamboj I; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Collaborative Opportunities for Research, Training, and Excellence in Innovation (CORTEX), Westwood, KC. Electronic address: i.ishitakamboj@gmail.com., Habib A; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Chang D; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC., Rashid A; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS., Vegel A; Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA., Graf K; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Division of Hematology Oncology, Medical University of South Carolina, Charleston, SC., Struble E; Division of Hematology, Oncology and Blood & Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA., Mushtaq MU; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS., Mahmoudjafari Z; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS., Green K; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Division of Hematology Oncology, Medical University of South Carolina, Charleston, SC., Khan AM; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Strouse CS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Division of Hematology, Oncology and Blood & Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA., McGuirk JP; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS., Hashmi H; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Division of Hematology Oncology, Medical University of South Carolina, Charleston, SC; Division of Hematology-oncology, Memorial Sloan Kettering Cancer Center, New York City, NY., Shaikh H; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA., Atrash S; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC., Abdallah AO; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS., Ahmed N; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Collaborative Opportunities for Research, Training, and Excellence in Innovation (CORTEX), Westwood, KC.
Source: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2026 Mar; Vol. 26 (3), pp. e315-e324. Date of Electronic Publication: 2025 Sep 28.
Publication Type: Journal Article; Comparative Study; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41139561
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kamboj+I%22">Kamboj I</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Collaborative Opportunities for Research, Training, and Excellence in Innovation (CORTEX), Westwood, KC. Electronic address: i.ishitakamboj@gmail.com.<br /><searchLink fieldCode="AU" term="%22Habib+A%22">Habib A</searchLink>; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.<br /><searchLink fieldCode="AU" term="%22Chang+D%22">Chang D</searchLink>; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC.<br /><searchLink fieldCode="AU" term="%22Rashid+A%22">Rashid A</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS.<br /><searchLink fieldCode="AU" term="%22Vegel+A%22">Vegel A</searchLink>; Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA.<br /><searchLink fieldCode="AU" term="%22Graf+K%22">Graf K</searchLink>; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Division of Hematology Oncology, Medical University of South Carolina, Charleston, SC.<br /><searchLink fieldCode="AU" term="%22Struble+E%22">Struble E</searchLink>; Division of Hematology, Oncology and Blood & Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA.<br /><searchLink fieldCode="AU" term="%22Mushtaq+MU%22">Mushtaq MU</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS.<br /><searchLink fieldCode="AU" term="%22Mahmoudjafari+Z%22">Mahmoudjafari Z</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS.<br /><searchLink fieldCode="AU" term="%22Green+K%22">Green K</searchLink>; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Division of Hematology Oncology, Medical University of South Carolina, Charleston, SC.<br /><searchLink fieldCode="AU" term="%22Khan+AM%22">Khan AM</searchLink>; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.<br /><searchLink fieldCode="AU" term="%22Strouse+CS%22">Strouse CS</searchLink>; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Division of Hematology, Oncology and Blood & Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA.<br /><searchLink fieldCode="AU" term="%22McGuirk+JP%22">McGuirk JP</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS.<br /><searchLink fieldCode="AU" term="%22Hashmi+H%22">Hashmi H</searchLink>; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Division of Hematology Oncology, Medical University of South Carolina, Charleston, SC; Division of Hematology-oncology, Memorial Sloan Kettering Cancer Center, New York City, NY.<br /><searchLink fieldCode="AU" term="%22Shaikh+H%22">Shaikh H</searchLink>; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA.<br /><searchLink fieldCode="AU" term="%22Atrash+S%22">Atrash S</searchLink>; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC.<br /><searchLink fieldCode="AU" term="%22Abdallah+AO%22">Abdallah AO</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS.<br /><searchLink fieldCode="AU" term="%22Ahmed+N%22">Ahmed N</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS; Collaborative Opportunities for Research, Training, and Excellence in Innovation (CORTEX), Westwood, KC.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101525386%22">Clinical lymphoma, myeloma & leukemia</searchLink> [Clin Lymphoma Myeloma Leuk] 2026 Mar; Vol. 26 (3), pp. e315-e324. <i>Date of Electronic Publication: </i>2025 Sep 28.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Comparative Study; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101525386 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2152-2669 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221522669%22">21522669 </searchLink><i>NLM ISO Abbreviation: </i>Clin Lymphoma Myeloma Leuk <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41139561
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.clml.2025.09.015
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e315
    Titles:
      – TitleFull: Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kamboj I
      – PersonEntity:
          Name:
            NameFull: Habib A
      – PersonEntity:
          Name:
            NameFull: Chang D
      – PersonEntity:
          Name:
            NameFull: Rashid A
      – PersonEntity:
          Name:
            NameFull: Vegel A
      – PersonEntity:
          Name:
            NameFull: Graf K
      – PersonEntity:
          Name:
            NameFull: Struble E
      – PersonEntity:
          Name:
            NameFull: Mushtaq MU
      – PersonEntity:
          Name:
            NameFull: Mahmoudjafari Z
      – PersonEntity:
          Name:
            NameFull: Green K
      – PersonEntity:
          Name:
            NameFull: Khan AM
      – PersonEntity:
          Name:
            NameFull: Strouse CS
      – PersonEntity:
          Name:
            NameFull: McGuirk JP
      – PersonEntity:
          Name:
            NameFull: Hashmi H
      – PersonEntity:
          Name:
            NameFull: Shaikh H
      – PersonEntity:
          Name:
            NameFull: Atrash S
      – PersonEntity:
          Name:
            NameFull: Abdallah AO
      – PersonEntity:
          Name:
            NameFull: Ahmed N
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2026 Mar
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2152-2669
          Numbering:
            – Type: volume
              Value: 26
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Clinical lymphoma, myeloma & leukemia
              Type: main
ResultId 1